The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
BackgroundLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
(2006) · Surgery · doi:10.1016/s0039-6060(06)00616-7 · Cited by 1,642
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329 · cited 1×
“2,4 There has been no endorsement of an upper age limit as an absolute contraindication, but older individuals have worse long-term survival following lung transplant.”
BackgroundSelf-citationChambers, D. C., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Meiser, B., Potena, L., Rossano, J. W., Toll, A. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.001 · Cited by 1,269
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
The bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093
Orens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Self-citationPrediction of mortality in patients with cystic fibrosis
Kerem, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261804 · Cited by 993
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846 · cited 1×
“289,290 Furthermore, specific clinical scenarios known to equate to a high-risk profile need to be considered.”
BackgroundRisk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Pulmonary hypertension in chronic lung disease and hypoxia
Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01914-2018 · Cited by 757
Spectrum of fibrotic lung diseases
Wijsenbeek, M., & Cottin, V. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2005230 · Cited by 736
Self-citationHoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00740-2017 · Cited by 660 · cited 1×
“288 Finally, this approach, similar to the RSS, still needs to be validated prospectively.”
MethodCottin, V., Hirani, N., Hotchkin, D. L., Nambiar, A. M., Ogura, T., Otaola, M., Skowasch, D., Park, J. S., Poonyagariyagorn, H. K., Wuyts, W. A., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0076-2018 · Cited by 656
Predicting Survival in Patients With Pulmonary Arterial Hypertension
Benza, R. L., Gomberg-Maitland, M., Elliott, C. G., Farber, H. W., Foreman, A. J., Frost, A. E., McGoon, M. D., Pasta, D. J., Selej, M., Burger, C. D., et al. (2019) · Chest · doi:10.1016/j.chest.2019.02.004 · Cited by 643
Rossano, J. W., Cherikh, W. S., Chambers, D. C., Goldfarb, S., Hayes, D., Khush, K. K., Kucheryavaya, A. Y., Toll, A. E., Levvey, B. J., Meiser, B., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.018 · Cited by 637
Rosenzweig, E. B., Abman, S. H., Adatia, I., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01916-2018 · Cited by 629 · cited 1×
“136,137 Children with PAH in the high-risk category and on optimal therapy without improvement should be listed for lung transplantation.”
BackgroundMaher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
Johnson, S. R., Cordier, J. F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00076209 · Cited by 590
Wells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 589
International guidelines for the selection of lung transplant candidates
Maurer, J. R., Frost, A. E., Estenne, M., Higenbottam, T., & Glanville, A. R. (1998) · Transplantation · doi:10.1097/00007890-199810150-00033 · Cited by 562
Self-citationPredicting Survival Across Chronic Interstitial Lung Disease
Ryerson, C. J., Vittinghoff, E., Ley, B., Lee, J. S., Mooney, J. J., Jones, K. D., Elicker, B. M., Wolters, P. J., Koth, L. L., King, T. E., et al. (2014) · Chest · doi:10.1378/chest.13-1474 · Cited by 558
Pediatric Pulmonary Hypertension
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze‐Neick, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.028 · Cited by 543
Prognostic Factors in COPD Patients Receiving Long-term Oxygen Therapy
Oswald–Mammosser, M., Weitzenblum, E., Quoix, É., Moser, G., Chaouat, A., Charpentier, C., & Kessler, R. (1995) · CHEST Journal · doi:10.1378/chest.107.5.1193 · Cited by 516
Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score
Martínez-García, M. Á., de Gracia, J., Vendrell Relat, M., Girón, R.-M., Máiz Carro, L., de la Rosa Carrillo, D., & Olveira, C. (2014) · European Respiratory Journal · doi:10.1183/09031936.00026313 · Cited by 503
Chambers, D. C., Cherikh, W. S., Goldfarb, S. B., Hayes, D., Kucheryavaya, A. Y., Toll, A. E., Khush, K. K., Levvey, B. J., Meiser, B., Rossano, J. W., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.020 · Cited by 498 · cited 1×
“153,270 Finally, the risk of colorectal cancer is increased in CF compared to age-matched controls, and transplant programs should screen CF candidates with colonoscopy beginning at age 40 years based on the 2017 CF Foundation Guidelines.”
BackgroundHansmann, G., Köestenberger, M., Alastalo, T.-P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.022 · Cited by 444
Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction
Martínez, F. J., Foster, G. L., Curtis, J. L., Criner, G. J., Weinmann, G. G., Fishman, A. P., DeCamp, M. M., Benditt, J. O., Sciurba, F. C., Make, B. J., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1677oc · Cited by 441
Criner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., Sciurba, F. C., Shah, P. L., Wahidi, M. M., de Oliveira, H. G., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201803-0590oc · Cited by 428
Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis
Esther, C. R., Esserman, D. A., Gilligan, P., Kerr, A., & Noone, P. G. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.12.001 · Cited by 410
Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive
Newton, C. A., Batra, K., Torrealba, J., Kozlitina, J., Glazer, C. S., Aravena, C., Meyer, K., Raghu, G., Collard, H. R., & Garcia, C. K. (2016) · European Respiratory Journal · doi:10.1183/13993003.00308-2016 · Cited by 400
Kemp, S. V., Slebos, D., Kirk, A. J. B., Kornaszewska, M., Carron, K., Ek, L., Broman, G., Hillerdal, G., Mal, H., Pison, C. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1327oc · Cited by 397
George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30355-6 · Cited by 349
Dew, M. A., Rosenberger, E. M., Myaskovsky, L., DiMartini, A. F., DeVito Dabbs, A. J., Posluszny, D. M., Steel, J., Switzer, G. E., Shellmer, D. A., & Greenhouse, J. B. (2015) · Transplantation · doi:10.1097/tp.0000000000000901 · Cited by 304
Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient Registry
Kerem, E., Viviani, L., Zolin, A., MacNeill, S., Hatziagorou, E., Ellemunter, H., Drevinek, P., Gulmans, V., Krivec, U., & Olesen, H. (2014) · European Respiratory Journal · doi:10.1183/09031936.00166412 · Cited by 296 · cited 1×
“…mycobacteria ( M. abscessus in particular) have been shown to increase the rate of lung function decline or death without transplant in advanced CF. 245,247,254,258,262 Implications of B. cenoce-pacia, M. abscessus , or L. prolificans are described above (infectious disease risk factors).”
BackgroundThe natural history of progressive fibrosing interstitial lung diseases
Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00085-2020 · Cited by 293
Moghadam‐Kia, S., Oddis, C. V., Sato, S., et al. (2015) · Arthritis Care & Research · doi:10.1002/acr.22728 · Cited by 279
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis
de Boer, K., Vandemheen, K. L., Tullis, E., Doucette, S., Fergusson, D., Freitag, A., Paterson, N., Jackson, M., Lougheed, M. D., Kumar, V., et al. (2011) · Thorax · doi:10.1136/thx.2011.161117 · Cited by 271
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
Mayer-Hamblett, N., Rosenfeld, M., Emerson, J., Goss, C. H., & Aitken, M. L. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200202-087oc · Cited by 269
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management
Wijsenbeek, M. S., Kreuter, M., Olson, A. L., Fischer, A., Bendstrup, E. M., Wells, C. D., Denton, C. P., Mounir, B., Zouad-Lejour, L., Quaresma, M., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1647040 · Cited by 268
Self-citationBelli, L. S., Perricone, G., Adam, R., Cortesi, P. A., Strazzabosco, M., Facchetti, R., Karam, V., Salizzoni, M., Andujar, R. L., Fondevila, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.010 · Cited by 251
The impact of cognitive function on medication management: Three studies.
Stilley, C. S., Bender, C. M., Dunbar-Jacob, J., Sereika, S., & Ryan, C. M. (2010) · Health Psychology · doi:10.1037/a0016940 · Cited by 248
Predictors of mortality in pulmonary sarcoidosis
Kirkil, G., Lower, E. E., & Baughman, R. P. (2018) · Chest · doi:10.1016/j.chest.2017.07.008 · Cited by 243
Scott, M. K. D., Quinn, K., Li, Q., Carroll, R. J., Warsinske, H., Vallania, F., Chen, S., Carns, M. A., Aren, K., Sun, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30508-3 · Cited by 240
Ramos, K. J., Smith, P. J., McKone, E. F., Pilewski, J. M., Lucy, A., Hempstead, S. E., Tallarico, E., Faro, A., Rosenbluth, D. B., Gray, A. L., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.03.002 · Cited by 227 · cited 2×
“134,261 These goals will continue to be important even in the era of highly effective CFTR modulators, particularly in patients who are ineligible for, cannot tolerate, or do not respond to such therapy, or if adverse long-term clinical effects arise.”
BackgroundSelf-citationFrailty phenotypes, disability, and outcomes in adult candidates for lung transplantation
Singer, J. P., Diamond, J. M., Gries, C. J., McDonnough, J., Blanc, P. D., Shah, R., Dean, M. Y., Hersh, B., Wolters, P. J., Tokman, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1150oc · Cited by 224 · cited 1×
“49,50 51-53 However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
BackgroundSelf-citationProgressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Nasser, M., Larrieu, S., Si-Mohamed, S. A., Ahmad, K., Boussel, L., Brevet, M., Chalabreysse, L., Fabre, C., Marque, S., Revel, D., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02718-2020 · Cited by 220
Hoeper, M. M., Benza, R. L., Corris, P., de Perrot, M., Fadel, E., Keogh, A. M., Kühn, C., Savale, L., & Klepetko, W. (2019) · European Respiratory Journal · doi:10.1183/13993003.01906-2018 · Cited by 216
Massive hemoptysis in cystic fibrosis
Flume, P. A., Yankaskas, J. R., Ebeling, M., Hulsey, T., & Clark, L. L. (2005) · Chest · doi:10.1378/chest.128.2.729 · Cited by 215
Obesity and underweight are associated with an increased risk of death after lung transplantation
Lederer, D. J., Wilt, J. S., D'Ovidio, F., Bacchetta, M. D., Shah, L., Ravichandran, S., Lenoir, J., Klein, B., Sonett, J. R., & Arcasoy, S. M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0425oc · Cited by 198
Self-citationPredicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis
Jacob, J., Bartholmai, B. J., Rajagopalan, S., van Moorsel, C. H. M., van Es, H. W., van Beek, F. T., Struik, M. H. L., Kokosi, M., Egashira, R., Brun, A. L., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201711-2174oc · Cited by 198
Bellou, V., Belbasis, L., Konstantinidis, A. K., Tzoulaki, I., & Evangelou, E. (2019) · BMJ · doi:10.1136/bmj.l5358 · Cited by 197
Cystic fibrosis colorectal cancer screening consensus recommendations
Hadjiliadis, D., Khoruts, A., Zauber, A. G., Hempstead, S. E., Maisonneuve, P., Lowenfels, A. B., Braid, A. L., Cullina, J., Daggett, A., Fink, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.012 · Cited by 195
Lung disease as a determinant of cognitive decline and dementia
Dodd, J. W. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0116-3 · Cited by 192
Dew, M. A., DiMartini, A. F., Dobbels, F., Grady, K. L., Jowsey‐Gregoire, S. G., Kaan, A., Kendall, K., Young, Q., Abbey, S. E., Butt, Z. A., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.03.005 · Cited by 192 · cited 3×
“86 Despite wide recognition of the importance of psychosocial functioning for favorable lung transplant outcomes, few psychosocial contraindications are considered absolute.”
BackgroundSelf-citationCriner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0383oc · Cited by 182 · cited 1×
“181-183 Survival benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the…”
BackgroundRisk factors for death of patients with cystic fibrosis awaiting lung transplantation
Belkin, R. A., Henig, N. R., Singer, L. G., Chaparro, C., Rubenstein, R. C., Xie, S. X., Yee, J. Y., Kotloff, R. M., Lipson, D. A., & Bunin, G. R. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1369oc · Cited by 180
Self-citationEffect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria
Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0402oc · Cited by 180
Newton, C. A., Oldham, J. M., Ley, B., Anand, V. C., Adegunsoye, A., Liu, G. Y., Batra, K., Torrealba, J. R., Kozlitina, J., Glazer, C. S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01641-2018 · Cited by 180
Alexander, B. D., Petzold, E. W., Reller, L. B., Palmer, S. M., Davis, R. D., Woods, C. W., & LiPuma, J. J. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02186.x · Cited by 177
Impact of Burkholderia Infection on Lung Transplantation in Cystic Fibrosis
Murray, S., Charbeneau, J., Marshall, B. C., & LiPuma, J. J. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1834oc · Cited by 177 · cited 1×
“cenocepacia has been associated with post-transplant infections and increased mortality especially within the first 6-12 months.(72,73) While it may be considered an absolute contraindication at many centers, patients may be candidates at specialized centers that have attained satisfactory outcomes with protocols impl…”
BackgroundHayes, D., Cherikh, W. S., Chambers, D. C., Harhay, M. O., Khush, K. K., Lehman, R. R., Meiser, B., Rossano, J. W., Hsich, E., Potena, L., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.003 · Cited by 168
Risk of death in cystic fibrosis patients with severely compromised lung function
Milla, C. E., & Warwick, W. J. (1998) · Chest · doi:10.1378/chest.113.5.1230 · Cited by 167
Pneumothorax in cystic fibrosis
Flume, P. A., Strange, C., Ye, X., Ebeling, M., Hulsey, T., & Clark, L. L. (2005) · Chest · doi:10.1378/chest.128.2.720 · Cited by 164
Hoetzenecker, K., Donahoe, L., Yeung, J. C., Azad, S., Fan, E., Ferguson, N. D., Del Sorbo, L., de Perrot, M., Pierre, A., Yasufuku, K., et al. (2018) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.09.161 · Cited by 164 · cited 2×
“143,144 Indications for ECLS include hypercapnic respiratory failure, hypoxic respiratory failure, and right ventricular failure.”
BackgroundSelf-citationAl-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16318 · Cited by 163 · cited 2×
“Malignancy with high risk of recurrence or death is an absolute contraindication, but it is increasingly acknowledged in the context of lung transplant that not all neoplastic diseases are equal.(13,14) Certain malignancies may not be significantly affected by immunosuppression and some may be managed post-transplant…”
BackgroundSurvival in Sensitized Lung Transplant Recipients With Perioperative Desensitization
Tinckam, K. J., Keshavjee, S., Chaparro, C., Barth, D., Azad, S., Binnie, M., Chow, C. W., de Perrot, M., Pierre, A. F., Waddell, T. K., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13076 · Cited by 161 · cited 1×
“However, some centers describe successful lung transplantation despite positive cross match.(62,63) Cut-off levels for organ acceptance and the optimal methods for detection of functional donor specific antibodies have not been determined.”
BackgroundSelf-citationImpact of the lung allocation score on lung transplantation for pulmonary arterial hypertension
Chen, H., Shiboski, S. C., Golden, J. A., Gould, M. K., Hays, S. R., Hoopes, C. W., & De Marco, T. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1603oc · Cited by 161
OPTN/SRTR 2019 annual data report: lung
Valapour, M., Lehr, C. J., Skeans, M. A., Smith, J. M., Miller, E., Goff, R., Foutz, J., Israni, A. K., Snyder, J. J., & Kasiske, B. L. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16495 · Cited by 161 · cited 1×
“8 With increasing experience in older recipients, several studies have shown that carefully selected older recipients may have the same short-term survival as younger recipients.”
BackgroundSelf-citationFadel, É., Mercier, O. M., Mussot, S., Leroy-Ladurie, F., Cerrina, J., Chapelier, A. R., Simonneau, G., & Dartevelle, P. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.02.039 · Cited by 156 · cited 1×
“156-159 Similarly, patients with advanced lung disease and cardiac pathology amenable to surgical repair may be candidates for lung transplant concurrent with the appropriate correc-tive cardiac procedure.”
BackgroundFundoplication after lung transplantation prevents the allograft dysfunction associated with reflux
Hartwig, M. G., Anderson, D. J., Onaitis, M. W., Reddy, S., Snyder, L. D., Lin, S. S., & Davis, R. D. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.04.035 · Cited by 155 · cited 2×
“38,39 40-42 In one study, when stratified by degree of obesity, the risk of mortality was increased for patients with a BMI > 35 and not in those with BMI 30-34.9.”
BackgroundInfluentialSelf-citationSato, S., Masui, K., Nishina, N., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key060 · Cited by 155
Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient
Hamadeh, R., Ardehali, A., Locksley, R. M., & York, M. K. (1988) · Chest · doi:10.1378/chest.94.2.432 · Cited by 151
Wickerson, L. M., Rozenberg, D., Janaudis‐Ferreira, T., Deliva, R. D., Lo, V., Beauchamp, G., Helm, D., Gottesman, C., Mendes, P. L., Vieira, L., et al. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i3.517 · Cited by 143 · cited 1×
“Pre- and post-transplant pulmonary rehabilitation should be recommended for transplant candidates and recipients.(57,58) Human Leucocyte Antigen (HLA) Antibodies: Elevated HLA specific antibodies detected in peripheral blood may make finding a compatible donor difficult and may predict poor outcomes.”
BackgroundBody composition and mortality after adult lung transplantation in the United States
Singer, J. P., Peterson, E. R., Snyder, M. E., Katz, P. P., Golden, J. A., D’Ovidio, F., Bacchetta, M., Sonett, J. R., Kukreja, J., Shah, L., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0973oc · Cited by 133 · cited 2×
“42 These patients should be encouraged to lose weight as the magnitude of pre-trans-plant weight loss is directly correlated with improvements in post-transplant survival for candidates who are not underweight.”
BackgroundInfluentialSelf-citationFrailty phenotypes and mortality after lung transplantation: a prospective cohort study
Singer, J. P., Diamond, J. M., Anderson, M. R., Katz, P. P., Covinsky, K., Oyster, M., Blue, T., Soong, A., Kalman, L., Shrestha, P., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14873 · Cited by 133
Self-citationInoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Newton, C. A., Kozlitina, J., Lines, J. R., Kaza, V., Torres, F., & Garcia, C. K. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.02.005 · Cited by 132
Holzmann, D., Speich, R., Kaufmann, T., Laube, I., Russi, E. W., Simmen, D., Weder, W., & Boehler, A. (2004) · Transplantation · doi:10.1097/01.tp.0000100467.74330.49 · Cited by 127
Lung transplantation: indications and contraindications
Weill, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.141 · Cited by 127 · cited 1×
“163 In addition, one study has suggested there may be no survival advantage with lung-liver transplant when compared to matched single-organ lung transplant recipients with an equivalent degree of liver dysfunction, suggesting a need for more precise criteria to determine optimal lung-liver…”
BackgroundSelf-citationTherapies for refractory hypoxemia in acute respiratory distress syndrome
Pipeling, M. R., & Fan, E. (2010) · JAMA · doi:10.1001/jama.2010.1752 · Cited by 126
Spectrum of Fibrotic Lung Diseases
Karim, F., van Laar, J. A. M., & van Hagen, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031135 · Cited by 126
Twenty-year experience with extracorporeal life support as bridge to lung transplantation
Benazzo, A., Schwarz, S., Frommlet, F., Schweiger, T., Jaksch, P., Schellongowski, P., Staudinger, T., Klepetko, W., Lang, G., Hoetzenecker, K., et al. (2019) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.02.048 · Cited by 126 · cited 2×
“143,144 Indications for ECLS include hypercapnic respiratory failure, hypoxic respiratory failure, and right ventricular failure.”
BackgroundMarks, W. H., Florence, L., Lieberman, J., Chapman, P., Howard, D., Roberts, P., & Perkinson, D. (1996) · Transplantation · doi:10.1097/00007890-199606270-00018 · Cited by 125
Adherence to the Medical Regimen During the First Two Years After Lung Transplantation
Dew, M. A., DiMartini, A. F., De Vito Dabbs, A., Zomak, R., De Geest, S., Dobbels, F., Myaskovsky, L., Switzer, G. E., Unruh, M., Steel, J. L., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318160135f · Cited by 124
Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study
Verleden, S. E., Todd, J. L., Sato, M., Palmer, S. M., Martinu, T., Pavlisko, E. N., Vos, R., Neyrinck, A., Van Raemdonck, D., Saito, T., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13281 · Cited by 123 · cited 1×
“1,139,140 Pneumothorax / Pleurodesis : When possible, management of a pneumothorax in a patient who may be a potential lung transplant candidate should be discussed with a transplant center.”
BackgroundThabut, G., Ravaud, P., Christie, J. D., Castier, Y., Fournier, M., Mal, H., Lesèche, G., & Porcher, R. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1283oc · Cited by 122
Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema
Martínez, F. J., Han, M. K., Andrei, A., Wise, R. A., Murray, S., Curtis, J. L., Sternberg, A., Criner, G. J., Gay, S. E., Reilly, J. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1383oc · Cited by 120 · cited 1×
“175,177,178 While DLCO has not been shown to be an independent predictor of mortality in COPD, a low DLCO has been associated with increased COPD symptoms, reduced exercise performance, and severe exacerbation risk, and thus, also may prompt consideration of referral.”
BackgroundBehr, J., Neuser, P., Prasse, A., et al. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0462-y · Cited by 120
Pulmonary rehabilitation in lung transplant candidates
Li, M. M., Mathur, S., Chowdhury, N., Helm, D., & Singer, L. G. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.04.002 · Cited by 116 · cited 1×
“57,58 59-61 However, some centers describe successful lung transplantation despite positive cross match.”
BackgroundWhen to consider lung transplantation for COVID-19
Cypel, M., & Keshavjee, S. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30393-3 · Cited by 116
Self-citationKillian, M., Schuman, D. L., Mayersohn, G. S., & Triplett, K. N. (2018) · Pediatric Transplantation · doi:10.1111/petr.13188 · Cited by 113
de Perrot, M. E., Granton, J. T., McRae, K. M., Pierre, A. F., Singer, L. G., Waddell, T. K., & Keshavjee, S. H. (2012) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.08.055 · Cited by 111
de Perrot, M., Chernenko, S., Waddell, T. K., Shargall, Y., Pierre, A. F., Hutcheon, M., & Keshavjee, S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.188 · Cited by 109
Lobo, L. J., Chang, L. C., Esther, C. R., Gilligan, P. H., Tulu, Z., & Noone, P. G. (2013) · Clinical Transplantation · doi:10.1111/ctr.12140 · Cited by 108 · cited 1×
“64,65 66-69 Thus, patients with M. abscessus should be managed at centers with expertise and protocols for managing this infection.”
BackgroundThe US experience with lung transplantation for pulmonary lymphangioleiomyomatosis
Kpodonu, J., Massad, M. G., Chaer, R. A., Caines, A., Evans, A., Snow, N. J., & Geha, A. S. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.09.013 · Cited by 106
The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis
Ando, K., Kurihara, M., Kataoka, H., Ueyama, M., Togo, S., Sato, T., Doi, T., Iwakami, S.-I., Takahashi, K., Seyama, K., et al. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.03.002 · Cited by 106
Date, H., Sato, M., Aoyama, A., Yamada, T., Mizota, T., Kinoshita, H., Handa, T., Tanizawa, K., Chin, K., Minakata, K., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu350 · Cited by 106
Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective
King, B. J., Iyer, H., Leidi, A. A., & Carby, M. R. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.05.040 · Cited by 105 · cited 1×
“32,33 Anti-reflux surgery pre-transplant and early post-transplant has been associated with a decrease in the development of early allograft dysfunction.”
BackgroundJackson, A., Cropper, J., Pye, R., Junius, F., Malouf, M., & Glanville, A. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.12.006 · Cited by 105
Self-citationMartin, C., Hamard, C., Kanaan, R., Boussaud, V., Grenet, D., Abély, M., Hubert, D., Munck, À., Lemonnier, L., & Burgel, P. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.09.002 · Cited by 103 · cited 1×
“134,261 These goals will continue to be important even in the era of highly effective CFTR modulators, particularly in patients who are ineligible for, cannot tolerate, or do not respond to such therapy, or if adverse long-term clinical effects arise.”
BackgroundRecurrence of bronchioloalveolar carcinoma in transplanted lungs
Garver, R. I., Zorn, G. L., Wu, X., McGiffin, D. C., Young, K. R., & Pinkard, N. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904083401403 · Cited by 102
Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation
Verleden, S. E., Vanaudenaerde, B. M., Emonds, M., Raemdonck, D. E. V., Neyrinck, A., Verleden, G. M., & Vos, R. (2017) · European Respiratory Journal · doi:10.1183/13993003.01248-2017 · Cited by 100
Diffusing Capacity of Carbon Monoxide in Assessment of COPD
Balasubramanian, A., MacIntyre, N. R., Henderson, R. J., Jensen, R. L., Kinney, G., Stringer, W. W., Hersh, C. P., Bowler, R. P., Casaburi, R., Han, M. K., et al. (2019) · Chest · doi:10.1016/j.chest.2019.06.035 · Cited by 100 · cited 1×
“179,180 The patient’s perception of an unacceptably poor quality of life may also be a consideration, albeit not the principal driver for referral, given the significant symptomatic benefits that transplant offers this patient population even in the face of an uncertain survival benefit.”
BackgroundLung transplantation for lymphangioleiomyomatosis: the European experience
Benden, C., Rea, F., Behr, J., Corris, P. A., Reynaud-Gaubert, M., Stern, M., Speich, R., & Boehler, A. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.09.014 · Cited by 99
Launay, D., Humbert, M., Berezne, A., Cottin, V., Allanore, Y., Couderc, L.-J., Bletry, O., Yaici, A., Hatron, P.-Y., Mouthon, L., et al. (2011) · Chest · doi:10.1378/chest.10-2473 · Cited by 99
Psychiatric predictors of long-term transplant-related outcomes in lung transplant recipients
Rosenberger, E. M., DiMartini, A. F., DeVito Dabbs, A. J., Bermudez, C. A., Pilewski, J. M., Toyoda, Y., & Dew, M. A. (2016) · Transplantation · doi:10.1097/tp.0000000000000824 · Cited by 97
Raghu, G., Richeldi, L., Jagerschmidt, A., Martin, V., Subramaniam, A., Ozoux, M., Espéret, C., & Soubrane, C. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1083 · Cited by 96
Ramos, K. J., Quon, B. S., Heltshe, S. L., Mayer-Hamblett, N., Lease, E. D., Aitken, M. L., Weiss, N. S., & Goss, C. H. (2017) · Chest · doi:10.1016/j.chest.2017.01.019 · Cited by 95 · cited 2×
“Special considerations in cystic fibrosis: Several comorbidities should be considered when evaluating candidates with CF. Infection or colonization with multi-drug resistant organisms including Burkholderia cepacia complex, Pseudomonas aeruginosa , and nontuberculous mycobacteria ( M. abscessus in particular) have been…”
BackgroundSelf-citationPulmonary veno-occlusive disease: recent progress and current challenges
Montani, D., O’Callaghan, D. S., Savale, L., Jaïs, X., Yaïci, A., Maitre, S., Dorfmuller, P., Sitbon, O., Simonneau, G., & Humbert, M. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.03.014 · Cited by 94
Psychosocial Predictors of Mortality Following Lung Transplantation
Smith, P. J., Blumenthal, J. A., Trulock, E. P., Freedland, K. E., Carney, R. M., Davis, R. D., Hoffman, B. M., & Palmer, S. M. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13447 · Cited by 93
Self-citationCommunity preferences for the allocation of solid organs for transplantation: a systematic review
Tong, A., Howard, K., Jan, S., Cass, A., Rose, J., Chadban, S., Allen, R. D., & Craig, J. C. (2010) · Transplantation · doi:10.1097/tp.0b013e3181cf1ee1 · Cited by 92
Vital, D., Hofer, M., Benden, C., Holzmann, D., & Boehler, A. (2013) · Respiration · doi:10.1159/000339627 · Cited by 91 · cited 1×
“263,264 264-267 Non-infectious comorbidities include malnutrition, which is common in CF patients approaching transplant and represents a potentially modifiable risk factor.”
BackgroundFrost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D. (2013) · Chest · doi:10.1378/chest.12-3023 · Cited by 90
Singh, N., Varghese, J., England, B. R., Solomon, J. J., Michaud, K., Mikuls, T. R., Healy, H. S., Kimpston, E. M., & Schweizer, M. L. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.005 · Cited by 90
Acuña, S. A., Huang, J. W., Daly, C., Shah, P. S., Kim, S. J., & Baxter, N. N. (2016) · Transplantation · doi:10.1097/tp.0000000000001192 · Cited by 89 · cited 1×
“Transplant centers should work closely with oncology specialists to evaluate each patient with a history of cancer to determine the stagespecific risk of recurrence or progression, which may be higher in the setting of immunosuppression, and to determine the necessary cancer-free period prior to listing.(15,16) Renal…”
BackgroundLung transplantation for lymphangioleiomyomatosis: the French experience
Reynaud-Gaubert, M., Mornex, J.-F., Mal, H., Treilhaud, M., Dromer, C., Quétant, S., Leroy-Ladurie, F., Guillemain, R., Philit, F., Dauriat, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817c15df · Cited by 87
on behalf of the IPF-PRO™ Registry investigators, Snyder, L. D., Neely, M. L., Hellkamp, A. S., O'Brien, E. C., de Andrade, J. A., Conoscenti, C., Leonard, T. B., Bender, S. D., Gulati, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1043-9 · Cited by 87
Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16324 · Cited by 87 · cited 2×
“Malignancy with high risk of recurrence or death is an absolute contraindication, but it is increasingly acknowledged in the context of lung transplant that not all neoplastic diseases are equal.(13,14) Certain malignancies may not be significantly affected by immunosuppression and some may be managed post-transplant…”
BackgroundOutcomes in systemic sclerosis-related lung disease after lung transplantation
Sottile, P. D., Iturbe, D., Katsumoto, T. R., Connolly, M. K., Collard, H. R., Leard, L. A., Hays, S., Golden, J. A., Hoopes, C., Kukreja, J., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e3182845f23 · Cited by 85 · cited 1×
“36,37 Hematologic abnormalities : Thrombocytopenia, leukopenia, or anemia may contribute to peri-operative complications and may limit use of optimal maintenance immunosuppression and necessary antimicrobial prophylaxis following lung transplant.”
BackgroundSelf-citationSmith, J. D., Ibrahim, M. W., Newell, H., Danskine, A. J., Soresi, S., Burke, M. M., Rose, M. L., & Carby, M. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.02.033 · Cited by 85 · cited 1×
“57,58 59-61 However, some centers describe successful lung transplantation despite positive cross match.”
BackgroundYoung, A., Vummidi, D., Visovatti, S., Homer, K., Wilhalme, H., White, E. S., Flaherty, K., McLaughlin, V., & Khanna, D. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40862 · Cited by 85
Psychiatric disorders as risk factors for adverse medical outcomes after solid organ transplantation
Rosenberger, E. M., Dew, M. A., Crone, C., & DiMartini, A. F. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283510928 · Cited by 83
Effects of Sinus Surgery on lung Transplantation Outcomes in Cystic Fibrosis
Leung, M., Rachakonda, L. P., Weill, D., & Hwang, P. H. (2008) · American Journal of Rhinology · doi:10.2500/ajr.2008.22.3146 · Cited by 83
Self-citationLung Transplant Outcomes in Patients With Pulmonary Fibrosis With Telomere-Related Gene Variants
Swaminathan, A. C., Neely, M. L., Frankel, C. W., Kelly, F. L., Petrovski, S., Durheim, M. T., Bush, E., Snyder, L. D., Goldstein, D. B., Todd, J. L., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.03.030 · Cited by 83 · cited 1×
“38,39 40-42 In one study, when stratified by degree of obesity, the risk of mortality was increased for patients with a BMI > 35 and not in those with BMI 30-34.9.”
BackgroundInfluentialUpala, S., Panichsillapakit, T., Wijarnpreecha, K., Jaruvongvanich, V., & Sanguankeo, A. (2016) · Transplant International · doi:10.1111/tri.12721 · Cited by 81
Miele, C. H., Schwab, K., Saggar, R., Duffy, E., Elashoff, D., Tseng, C.-H., Weigt, S., Charan, D., Abtin, F., Johannes, J., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201512-806oc · Cited by 81 · cited 1×
“36,37 Hematologic abnormalities : Thrombocytopenia, leukopenia, or anemia may contribute to peri-operative complications and may limit use of optimal maintenance immunosuppression and necessary antimicrobial prophylaxis following lung transplant.”
BackgroundTorrisi, S. E., Ley, B., Kreuter, M., Wijsenbeek, M., Vittinghoff, E., Collard, H. R., & Vancheri, C. (2019) · European Respiratory Journal · doi:10.1183/13993003.01587-2018 · Cited by 79
Self-citationChoong, C. K. C., Sweet, S. C., Guthrie, T. J., Mendeloff, E. N., Haddad, F. J., Schuler, P., de la Morena, M., & Huddleston, C. B. (2005) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.07.058 · Cited by 77
Pulmonary hypertension in cystic fibrosis with advanced lung disease
Hayes, D., Tobias, J. D., Mansour, H. M., Kirkby, S., McCoy, K. S., Daniels, C. J., & Whitson, B. A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1382oc · Cited by 77
Lung transplantation for lymphangioleiomyomatosis
Pechet, T. T., Meyers, B. F., Guthrie, T. J., Battafarano, R. J., Trulock, E. P., Cooper, J. D., & Patterson, G. A. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(03)00195-5 · Cited by 77
Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease
Morisset, J., Vittinghoff, E., Elicker, B. M., Hu, X., Le, S., Ryu, J. H., Jones, K. D., Haemel, A., Golden, J. A., Boin, F., et al. (2017) · Chest · doi:10.1016/j.chest.2017.06.009 · Cited by 77
van Beers, M., Janssen, D. J. A., Gosker, H. R., & Schols, A. M. W. J. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1533405 · Cited by 77
Qvist, T., Pressler, T., Thomsen, V. O., Skov, M., Iversen, M., & Katzenstein, T. L. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.02.035 · Cited by 76
Benza, R. L., Miller, D. P., Frost, A., Barst, R. J., Krichman, A. M., & McGoon, M. D. (2010) · Transplantation · doi:10.1097/tp.0b013e3181e49b83 · Cited by 75
Courtwright, A. M., El-Chemaly, S., Dellaripa, P. F., & Goldberg, H. J. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.12.013 · Cited by 73 · cited 1×
“29,30 Screening for extra-pulmonary systemic disease in collaboration with a multidisciplinary team, including rheumatologists, gastroenterologists, and neph-rologists, is essential in these candidates as cardiovascular (including conduction abnormalities, myocarditis, heart failure, and CAD),…”
BackgroundImpact of Pretransplant Anti-HLA Antibodies on Outcomes in Lung Transplant Candidates
Kim, M., Townsend, K. R., Wood, I. G., Boukedes, S., Guleria, I., Gabardi, S., El-Chemaly, S., Camp, P. C., Chandraker, A. K., Milford, E. L., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2160oc · Cited by 72
Dobbels, F., Vanhaecke, J., Desmyttere, A., Dupont, L., Nevens, F., & Geest, S. D. (2005) · Transplantation · doi:10.1097/01.tp.0000158430.06507.87 · Cited by 70
Combined lung and liver transplantation: Analysis of a single-center experience
Yi, S. G., Burroughs, S. G., Loebe, M. M., Scheinin, S. A., Seethamraju, H., Jyothula, S., Monsour, H., McFadden, R., Podder, H., Saharia, A., et al. (2013) · Liver Transplantation · doi:10.1002/lt.23770 · Cited by 70 · cited 1×
“161 ,162 Severely impaired liver synthetic function with an albumin < 2.0 g/dl, INR > 1.8 or the presence of severe ascites or encephalopathy should be considered contraindications.”
BackgroundInfluentialSchaffer, J. M., Singh, S. K., Joyce, D. L., Reitz, B. A., Robbins, R. C., Zamanian, R. T., & Mallidi, H. R. (2013) · Circulation · doi:10.1161/circulationaha.112.001080 · Cited by 69
Villavicencio, M. A., Axtell, A. L., Osho, A. A., Astor, T., Roy, N., Melnitchouk, S. I., D’Alessandro, D. A., Tolis, G., Raz, Y., Neuringer, I. P., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.04.060 · Cited by 68
Frailty trajectories in adult lung transplantation: a cohort study
Venado, A., McCulloch, C., Greenland, J. R., Katz, P., Soong, A., Shrestha, P., Hays, S., Golden, J., Shah, R., Leard, L. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.03.006 · Cited by 67 · cited 1×
“54 When considering frailty in lung transplant candidates, it should be noted that optimal assessment tools for frailty are not yet accepted and caution is warranted in using frailty for listing decisions.”
BackgroundSelf-citationHayes, D., Black, S. M., Tobias, J. D., Kirkby, S., Mansour, H. M., & Whitson, B. A. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.06.024 · Cited by 66
Simultaneous Thoracic and Abdominal Transplantation: Can We Justify Two Organs for One Recipient?
Wolf, J. H., Sulewski, M. E., Cassuto, J. R., Levine, M. H., Naji, A., Olthoff, K. M., Shaked, A. A., & Abt, P. L. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12291 · Cited by 65 · cited 1×
“153 Multi-organ transplant candidates have a higher waiting list mortality than individuals listed for single organ transplant 154 ; however, recipients who survive the difficult peri-operative period experience significant survival benefit, with favorable long-term survival.”
BackgroundMorisset, J., Vittinghoff, E., Lee, B. Y., Tonelli, R., Hu, X., Elicker, B. M., Ryu, J. H., Jones, K. D., Cerri, S., Manfredi, A., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.04.012 · Cited by 65
Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0308-z · Cited by 65
Factors Associated with Adherence to Treatment Regimens after Lung Transplantation
Teichman, B., Burker, E. J., Weiner, M., & Egan, T. M. (2000) · Progress in Transplantation · doi:10.7182/prtr.10.2.303p27p4406w71v7 · Cited by 65
Psychological symptom levels and their correlates in lung and heart-lung transplant recipients
Stilley, C. S., Amanda Dew, M., Stukas, A. A., Switzer, G. E., Manzetti, J. D., Keenan, R. J., & Griffith, B. P. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71189-8 · Cited by 64
Lo, W.-K., Goldberg, H. J., Wee, J., Fisichella, P. M., & Chan, W. W. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-2983-0 · Cited by 64 · cited 11×
“The most familiar of these is the BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-minute walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation.”
BackgroundInfluentialLo, W.-K., Burakoff, R., Goldberg, H. J., Feldman, N., & Chan, W. W. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.09.005 · Cited by 64 · cited 1×
“Esophageal Dysfunction / Gastrointestinal Dysmotility/ Gastroesophageal reflux (GER): Post-transplant GER is variably associated with increased risk of acute rejection, pulmonary infection and earlier development of chronic lung allograft dysfunction (CLAD).(32,33) Anti-reflux surgery pre-transplant and early post-tra…”
BackgroundPrognostic value of six minute walk test in cystic fibrosis adults
Martin, C., Chapron, J., Hubert, D., Kanaan, R., Honoré, I., Paillasseur, J.-L., Aubourg, F., Dinh-Xuan, A.-T., Dusser, D., Fajac, I., et al. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.10.001 · Cited by 63
Ribeiro Neto, M. L., Jellis, C. L., Joyce, E., Callahan, T. D., Hachamovitch, R., & Culver, D. A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201902-119cme · Cited by 63
Guler, S. A., Kwan, J. M., Leung, J. M., Khalil, N., Wilcox, P., & Ryerson, C. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.00647-2019 · Cited by 63
Psychosocial Issues in the Assessment and Management of Patients Undergoing Lung Transplantation
Barbour, K. A., Blumenthal, J. A., & Palmer, S. M. (2006) · CHEST Journal · doi:10.1378/chest.129.5.1367 · Cited by 61
Neurocognitive changes after lung transplantation
Smith, P. J., Rivelli, S., Waters, A., Reynolds, J., Hoyle, A., Flowers, M., Davis, R. D., Palmer, S. M., Mathew, J., Durheim, M., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201406-232oc · Cited by 60
Self-citationThe Declaration of Istanbul on Organ Trafficking and Transplant Tourism (2018 Edition)
(2019) · Transplantation · doi:10.1097/tp.0000000000002540 · Cited by 60
Yang, H., Xiang, P., Zhang, E., Guo, W., Shi, Y., Zhang, S., & Tong, Z. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008909 · Cited by 59
A 3-year prognostic score for adults with cystic fibrosis
Nkam, L., Lambert, J., Latouche, A., Bellis, G., Burgel, P., & Hocine, M. N. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.03.004 · Cited by 59 · cited 2×
“254 In this model a score of ≥ 4 was associated with a 55% risk of 3-year mortality, whereas a score of ≤ 2 carried only a 1% risk.”
BackgroundOutcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
Leuschner, G., Stocker, F., Veit, T., Kneidinger, N., Winter, H., Schramm, R., Weig, T., Matthes, S., Ceelen, F., Arnold, P., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.07.002 · Cited by 59
Pulmonary transplantation for advanced bronchioloalveolar carcinoma
Zorn, G. L., McGiffin, D. C., Young, K. R., Alexander, C. B., Weill, D., & Kirklin, J. K. (2003) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2003.72 · Cited by 58 · cited 1×
“321,322,330 Modifying the surgical approach as suggested to reduce aerogenous contamination of donor lungs at the time of implantation may mitigate the risk of relapse post-transplant.”
BackgroundSelf-citationThe feasibility of lung transplantation in HIV-seropositive patients
Kern, R. M., Seethamraju, H., Blanc, P. D., Sinha, N., Loebe, M., Golden, J., Kukreja, J., Scheinin, S., Hays, S., Kleinhenz, M. E., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201402-083oc · Cited by 58
Self-citationLancaster, T. S., Miller, J. R., Epstein, D. J., DuPont, N. C., Sweet, S. C., & Eghtesady, P. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.10.007 · Cited by 58
Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices
Jacob, J., Bartholmai, B. J., Rajagopalan, S., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.007 · Cited by 58
Kon, Z. N., Dahi, S., Evans, C. F., Byrnes, K. A., Bittle, G. J., Wehman, B., Rector, R. P., McCormick, B. M., Herr, D. L., Sanchez, P. G., et al. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.05.088 · Cited by 57
Hayanga, A. J., Aboagye, J. K., Hayanga, H. E., Morrell, M., Huffman, L., Shigemura, N., Bhama, J. K., D׳Cunha, J., & Bermudez, C. A. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.09.028 · Cited by 56 · cited 2×
“With increasing experience in older recipients, several studies have shown that carefully selected older recipients may have the same short-term survival as younger recipients.(9) However, the results are skewed by selection bias, reflecting the fact that most recipients over the age of 65 years undergoing lung transp…”
BackgroundColman, R., Singer, L. G., Barua, R., & Downar, J. (2015) · Palliative Medicine · doi:10.1177/0269216314566839 · Cited by 55 · cited 1×
“121,122 The risk and benefit of opioids prescribed to lung transplant candidates to palliate symptoms of pain or dyspnea should be considered on an individual basis.”
BackgroundProlonged Duration ECMO for ARDS: Futility, Native Lung Recovery, or Transplantation?
Rosenberg, A. A., Haft, J. W., Bartlett, R., Iwashyna, T. J., Huang, S. K., Lynch, W. R., & Napolitano, L. M. (2013) · ASAIO Journal · doi:10.1097/mat.0b013e3182a9e341 · Cited by 55
Heart or lung transplant outcomes in HIV-infected recipients
Koval, C. E., Farr, M., Krisl, J., Haidar, G., Pereira, M. R., Shrestha, N., Malinis, M. F., Mueller, N. J., Hannan, M. M., Grossi, P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.09.011 · Cited by 55
Hypoalbuminemia and early mortality after lung transplantation: a cohort study
Baldwin, M. R., Arcasoy, S. M., Shah, A., Schulze, P. C., Sze, J., Sonett, J. R., & Lederer, D. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03965.x · Cited by 54 · cited 1×
“46-48 It is also a predictor of poor survival for lung transplant candidates while on the waiting list including those who require ECLS prior to lung transplant.”
BackgroundSelf-citationTechniques and results of lobar lung transplantations
Mitilian, D., Sage, É., Puyo, P., et al. (2013) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezt353 · Cited by 54 · cited 1×
“141,142 Other considerations : Significant chest wall abnormalities, spinal deformities, or mediastinal fibrosis require individualized evaluation to determine surgical feasibility and degree of restriction anticipated post-transplant.”
BackgroundBest practices in the pediatric pretransplant psychosocial evaluation
Lefkowitz, D. S., Fitzgerald, C. J., Zelikovsky, N., Barlow, K., & Wray, J. (2014) · Pediatric Transplantation · doi:10.1111/petr.12260 · Cited by 54
MONTGOMERY, E. E., Macdonald, P. S., Newton, P. J., Chang, S., Jha, S. R., Hannu, M. K., Thomson, C., Havryk, A. P., & Malouf, M. A. (2019) · Transplantation · doi:10.1097/tp.0000000000002901 · Cited by 52
Impact of nutritional state on lung transplant outcomes
Chamogeorgakis, T., Mason, D. P., Murthy, S. C., Thuita, L., Raymond, D. P., Pettersson, G. B., & Blackstone, E. H. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.04.005 · Cited by 51
Lung transplantation following 107 days of extracorporeal membrane oxygenation
Iacono, A., Groves, S., Garcia, J., & Griffith, B. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.09.039 · Cited by 51
Yoon, H., Kim, T. H., Seo, J. B., Lee, S. M., Lim, S., Lee, H. N., Kim, N., Han, M., Kim, D. S., & Song, J. W. (2018) · Respirology · doi:10.1111/resp.13387 · Cited by 51 · cited 1×
“210,211 Predicting prognosis for individual patients with ILD remains difficult.”
BackgroundSmith, P. J., Snyder, L. D., Palmer, S. M., Hoffman, B. M., Stonerock, G. L., Ingle, K., Saulino, C. K., & Blumenthal, J. A. (2017) · Transplant International · doi:10.1111/tri.13094 · Cited by 51
Self-citationWeight loss prior to lung transplantation is associated with improved survival
Chandrashekaran, S., Keller, C. A., Kremers, W. K., Peters, S. G., Hathcock, M. A., & Kennedy, C. C. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.11.018 · Cited by 50 · cited 1×
“43,44 While low BMI has been associated with increased mortality, Cystic fibrosis (CF) recipients with BMI 17 kg/m 2 have a survival rate similar to other commonly transplanted patients.”
BackgroundDelirium affects length of hospital stay after lung transplantation
Smith, P. J., Rivelli, S. K., Waters, A. M., Hoyle, A., Durheim, M. T., Reynolds, J. M., Flowers, M., Davis, R. D., Palmer, S. M., Mathew, J. P., et al. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.09.010 · Cited by 49
Self-citationLung transplantation for advanced bronchioloalveolar carcinoma confined to the lungs
Paloyan, E. B., Swinnen, L. J., Montoya, A., Lonchyna, V., Sullivan, H. J., & Garrity, E. (2000) · Transplantation · doi:10.1097/00007890-200006150-00041 · Cited by 49 · cited 1×
“323,331 In summary, the risk associated with lung transplant in candidates with thoracic malignancy is high, and each center therefore needs to consider whether the possible benefit outweighs this risk and balance the overall need for prioritization of transplantable organs.”
BackgroundHeart–lung vs. double‐lung transplantation for idiopathic pulmonary arterial hypertension
Hill, C. C., Maxwell, B. G., Boulate, D., Haddad, F., Ha, R. V., Afshar, K., Weill, D., & Dhillon, G. S. (2015) · Clinical Transplantation · doi:10.1111/ctr.12628 · Cited by 48
Self-citationChakinala, M. M., Coyne, D. W., Benza, R. L., Frost, A. E., McGoon, M. D., Hartline, B. K., Frantz, R. P., Selej, M., Zhao, C., Mink, D. R., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.10.028 · Cited by 48
Survival in pulmonary arterial hypertension patients awaiting lung transplantation
Gomberg-Maitland, M., Glassner-Kolmin, C., Watson, S., Frantz, R., Park, M., Frost, A., Benza, R. L., & Torres, F. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.08.016 · Cited by 47
Psychosocial Challenges in Solid Organ Transplantation
Kuntz, K., Weinland, S. R., & Butt, Z. (2015) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-015-9435-6 · Cited by 47
The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis
Nishimoto, K., Fujisawa, T., Yoshimura, K., Enomoto, Y., Enomoto, N., Nakamura, Y., Inui, N., Sumikawa, H., Johkoh, T., Colby, T. V., et al. (2018) · Respirology · doi:10.1111/resp.13219 · Cited by 47
Smith, P. J., Blumenthal, J. A., Hoffman, B. M., Rivelli, S. K., Palmer, S. M., Davis, R. D., & Mathew, J. P. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201507-454oc · Cited by 46
Self-citationAssociation of chronic obstructive pulmonary disease with mild cognitive impairment and dementia
Kakkera, K., Padala, K. P., Kodali, M., & Padala, P. R. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000458 · Cited by 46
Badagliacca, R., Papa, S., Poscia, R., Valli, G., Pezzuto, B., Manzi, G., Torre, R., Gianfrilli, D., Sciomer, S., Palange, P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.11.015 · Cited by 46 · cited 1×
“289,290 Furthermore, specific clinical scenarios known to equate to a high-risk profile need to be considered.”
BackgroundBaldwin, M. R., Singer, J. P., Huang, D., Sell, J., Gonzalez, W. C., Pollack, L. R., Maurer, M. S., D’Ovidio, F. F., Bacchetta, M., Sonett, J. R., et al. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201612-1008oc · Cited by 45
Self-citation
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Wijsenbeek, M. S., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 576
Self-citationMaher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 435
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Bhakta, N. R., Bime, C., Kaminsky, D. A., McCormack, M. C., Thakur, N., Stanojevic, S., Baugh, A. D., Braun, L., Lovinsky‐Desir, S., Adamson, R., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202302-0310st · Cited by 316
“…is not used in the lung allocation score, the timing and listing for lung transplantation depends on — although it is not exclusively dependent on — FEV 1 (for COPD, cystic fi brosis, and lymphangioleiomyomatosis) and FVC (for interstitial lung disease) as a percentage of the predicted value (92).”
Progressive pulmonary fibrosis: an expert group consensus statement
Rajan, S. K., Cottin, V., Dhar, R., Danoff, S. K., Flaherty, K. R., Brown, K. K., Mohan, A., Renzoni, E. A., Mohan, M., V, Udwadia, Z., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.03187-2021 · Cited by 271
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
